Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

PURPOSE: Sunitinib in combination with docetaxel enhances antitumor activity in xenograft models of human breast and non-small cell lung cancer. We assessed the maximum tolerated doses (MTDs), safety, pharmacokinetic profiles, and preliminary efficacy of sunitinib plus docetaxel in patients with adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Robert, Francisco, Sandler, Alan, Schiller, Joan H., Liu, Glenn, Harper, Karen, Verkh, Lev, Huang, Xin, Ilagan, Jennifer, Tye, Lesley, Chao, Richard, Traynor, Anne M.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904454/
https://www.ncbi.nlm.nih.gov/pubmed/20043166
http://dx.doi.org/10.1007/s00280-009-1209-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904454/
https://www.ncbi.nlm.nih.gov/pubmed/20043166
http://dx.doi.org/10.1007/s00280-009-1209-0

Ejemplares similares